MIST biotech catalysts & pipeline

MILESTONE PHARMACEUTICALS INC · Data as of 2026-10-25

Upcoming catalysts

CARDAMYST (etripamil) — Regulatory decision

H1 2027

Regulatory review of the marketing authorization application for etripamil for PSVT in Europe remains on track for a decision from the European Medicines Agency (EMA) in the first half of 2027.

Source filing

etripamil nasal spray — Regulatory decision

H1 2027

A European decision on approval is expected by the first half of 2027.

Source filing

CARDAMYST (etripamil) — Conference presentation

Nov 2

Title: Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute PSVT Across Multiple Clinical Trials Presenter: David Bharucha, MD, Ph.D., FACC, Chief Medical Officer, Milestone Pharmaceuticals Day/Time: Monday, November 2, 12:00 pm PT Location: San Diego Convention Center, San Diego, CA

Source filing

CARDAMYST (etripamil) — Conference presentation

Nov 7

Title: Use of Etripamil in the RAPID Study for Recurrent PSVT After Prior Ablation Presenter: David Bharucha, MD, Ph.D., FACC, Chief Medical Officer, Milestone Pharmaceuticals Day/Time: Saturday, November 7, 12:50 pm CT Location: McCormick Place Convention Center , Chicago, IL

Source filing

Explore the free biotech catalyst calendar